At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 82 enrolled
Drug / intervention
Regorafenibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND
In Brief
A Phase 2 clinical trial evaluating Regorafenib for Pancreas Cancer and 6 related conditions. Completed, enrolled 82 participants across 1 site.
Detailed Summary
This is a single arm, single-stage, phase II trial to evaluate the activity of Regorafenib in patients with metastatic solid tumors (pancreatic cancer, ovarian cancer, melanoma, sarcoma, thymoma (type B2 - B3) and thymic carcinoma, who have progressed after standard therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreas Cancer, Ovarian Cancer, Melanoma, Sarcoma, Thymoma Type B3, Thymoma Type B2, Thymic Carcinoma
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedDec 2014
Primary CompletionDec 2017
Study CompletionAug 2020
TodayJul 2026
First PostedDec 4, 2014
Enrollment StartDec 1, 2014
Primary CompletionDec 1, 2017
Study CompletionAug 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 11.6 years ago
Interventions
Regorafenibdrug
oral therapy